Endocyte, Wedbush Analyst Upgrade, and the PSMA-617 Licensing Deal
NEW YORK, NY / ACCESSWIRE / October 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Endocyte, Inc. (ECYT), a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized, targeted therapies.
The past few days or so have been eventful for Endocyte and the company's stock has gained significant strength and popularity. The gains come on the back of a licensing agreement related to a development asset, a drug called PSMA-617. On October 2nd, the company announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH.
On October 3, 2017, Wedbush analyst David Nierengarten upgraded Endocyte to Buy and revised its target price.
Get details of the PSMA-617 licensing deal, and the Wedbush target price here READ MORE
Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/endocyte/
With PSMA-617, Endocyte is attempting to harness the toxicity of a chemotherapy agent and to simultaneously add an element of selectivity that will ensure that the drug only targets cancer cells and leaves healthy cells alone. Prostate cancer cells express an antigen called PSMA, which is the PSMA in the name of this drug, while healthy cells do not.
As per management, the PSMA-617 transaction is transformational to Endocyte, accelerating its path to commercialization. The company wants to go directly to phase 3 and expects to initiate during early 2018. Trial completion, assuming no overruns or exigencies, should come during 2020.
Details on the PSMA-617 potential, analyst's comments and financial review here READ MORE
Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/endocyte/
Disclosure
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
SOURCE: Traders News Source
